Abstract
Cytogenetic findings are becoming increasingly important for the management of patients with malignant diseases, especially for those with hematologic neoplasias. The detection of aquired somatic mutations may help to establish the diagnosis of a neoplastic disorder and to rule out reactive changes due to toxic injury, vitamin deficiency or infections. Before, however, a chromosome aberration found in tumor cells can be taken as tumorassociated change it should be ruled out by chromosome analysis on PHA-stimulated blood lymphocytes that this chromosome aberration does not represent a constitutional abnormality. It is now clear that certain so-called primary chromosome abnormalities of tumor cells are associated with distinct clinico-histological disease entities. During tumor evolution additional chromosome aberrations appear and may determine the clinical course of the disease. Even these so-called secondary chromosome aberrations are non-randomly distributed throughout the genome. Therefore, cytogenetic studies are essential to make a specified diagnosis, to classify malignant disorders, to characterize the degree of neoplastic progression, to predict the prognosis, to test for remission, and to establish when relapse occurs. Thus, cytogenetic data can be of great help to select the appropriate treatment strategy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Autio K, Turunen O, Pentilla P, Eramaa E, de la Chapelle A, and Schroeder J, 1979, Cancer Genet Cytogenet, 1, 147
Czepulkowski BH, Bhatt B, and Rooney DE in: Rooney DE and Czepulkowski BH: Human Cytogenetics 1992, 11 ff.
Gahrton G, Zech L, Robert, KH, and Bird AG, 1979, New Engl J Med 301, 438
Garipidou V, and Secker-Walker LM, 1991, Cancer Genet Cytogenet 52, 107–111
Hagemeijer A, Smith EME, and D Bootsma, 1979, Cytogenet Cell Genet 23, 208–212
Lichter P, and Ward DC, 1990, Nature 345, 93–95
Metzke S, 1995, Leukaemia 9, 1413–1414
Pinkel D, Straume T, and Gray JW, 1986, Proc Natl Acad Sci USA 83, 2934–2938
Pirc-Danoewinata H, Onderka E, Porenta G, Kundi M, Nowotny H, Schlögl E, Heinz R, Kreiner G, and Marosi C, 1995, Cancer Genet Cytogenet, 80, 129–134
Ross FM, and Robert KH, 1982, Cancer Genet Cytogenet, 25, 109
Sahar E, and Latt SA, 1978, Proc Natl Acad Sci USA, 75, 5650–5654
Siebert R, and Weber-Matthiesen K, 1997, Histochem Cell Biol, 108, 391–402
Trent J, Crickard K, Gibas Z, Goodacre A, Pathak S, and Sandberg AA, 1986, Cancer Genet Cytogenet, 157ff
Yunis JJ, 1982, Cancer Genet Cytogenet 7, 43–50
Zech L, Godal T, Hammarström L, Mellstedt H, Smith CIE, Tötterman T, and Went M, 1986, Cancer Genet Cytogenet 21, 67–77
Weber-Matthiesen K, Winkemann M, Müller-Hermelink A, Schlegelberger B, and Grote W, 1992, J Histochem Cytochem, 40, 171–175
Weber-Matthiesen K In: Clark M (ed.) In situ hybridization. Chapman & Hall, Weinheim, 1996 pp 67–90
Williams DL, Look AT, Melvin SL, Roberson PK, Dahl G, Flake T, and Stass S, 1984, Cell, 36, 101–109
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schlegelberger, B., Metzke, S., Harder, S., Zühlke-Jenisch, R., Zhang, Y., Siebert, R. (1999). Classical and Molecular Cytogenetics of Tumor Cells. In: Wegner, RD. (eds) Diagnostic Cytogenetics. Springer Lab Manual. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59918-7_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-59918-7_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-47813-0
Online ISBN: 978-3-642-59918-7
eBook Packages: Springer Book Archive